The DurAVR TAVR system from Anteris Technologies. A new biomimetic transcatheter aortic valve replacement (TAVR) system from Anteris Technologies could provide cardiologists with a new way to treat severe aortic stenosis (AS), according to new one-year data presented at SCAI 2024 Scientific Sessions, the annual meeting of the Society for Cardiovascular Angiography and Interventions (SCAI). The DurAVR TAVR system, made from a single piece of anti-calcification ADAPT tissue patented by Anteris.

One-year data presented at SCAI's annual meeting suggest interventional cardiologists could soon have a new way to treat severe aortic stenosis.

The popular AI chatbot's performance highlighted both its strengths and its weaknesses. It can answer multiple-choice questions, for example, but it struggles with consistency. 

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.

TAVR is also associated with a lower risk of acute kidney injury in this patient population. In-hospital mortality rates, however, are similar between the two treatment options. 

ACC President Cathie Biga explains how cardiologist employment models undergoing a profound transformation during an interview with Cardiovascular Digital Editor Dave Fornell at ACC 2024.

Hospital employment models, reimbursement policies and private equity have all led to a massive reduction in the number of cardiologists working for a private practice, ACC President Cathie Biga, MSN, told Cardiovascular Business.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."